B.r.a.h.m.s Gmbh

Anne Incamps

Markus Weigand

Tim Ziera

Thorsten Brenner

Maryann Stephanie Vogelsang

Bryan Krastins

Andre Schoenichen

Janin Schulte

Ingo Curdt

Manne Krop

Frauke Dreyer

Pierre-Emmanuel Charles

André SCHÖNICHEN

Markus Alexander Weigand

The present invention relates to a method for the diagnosis, prognosis, risk assessment, risk stratification, monitoring, therapy guidance and/or therapy control of a fungal infection, in particular invasive fungal infections (IFI) and/or the ruling in or ruling out of an fungal infection and/or the differential diagnosis of a fungal colonization vs. an invasive fungal infection in a subject, wherein in particular the subject has an increased risk of getting or having a fungal infection and/or the subject is in a critical disease state, particularly has an existing infection and/or a state of sepsis, particularly a septic shock. The method of the invention comprises determining the level of at least one marker selected from the group of ICAM1, AHSG, CPN1, FABP1, HRG, PIGR, RAP1A, THBS1, VCL, ET-1. Furthermore, the invention relates to a diagnostic assay and a kit for carrying out the method.

Biomarkers for the diagnosis of invasive fungal infections

The present invention relates to method for detecting a free histone protein in a biological sample of a subject, e.g. using an immunoassay or a mass spectrometric assay. It also pertains to a method for the diagnosis, prognosis, risk assessment, risk stratification and/or therapy control of a disease or medical condition, comprising detecting a free histone protein or peptide fragment thereof in a biological sample of a subject, wherein the presence of said free histone protein or fragment thereof is indicative for said disease or medical condition.

Free histone proteins as biomarkers

Growing community of inventors

Saint Victor la Coste, France

Anne Incamps